Compounds > nifurpirinol
Page last updated: 2024-12-11

nifurpirinol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

nifurpirinol: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6436061
CHEMBL ID2104627
CHEBI ID135000
SCHEMBL ID1650816
MeSH IDM0045678

Synonyms (48)

Synonym
D02513
13411-16-0
nifurpirinol (usan)
furanace (tn)
furpirinol
nifurpirinolum [inn-latin]
brn 1216943
nifurpirinol [usan:inn]
furanace
6-(2-(5-nitro-2-furyl)vinyl)-2-pyridinemethanol
nifurpirinol
furanace-10
6-hydroxymethyl-2-(2-(5-nitro-2-furyl)vinyl)-pyridine
6-hydroxymethyl-2-(2-(5-nitro-2-furyl)vinyl)pyridine
ccris 1046
furpyrinol
2-pyridinemethanol, 6-(2-(5-nitro-2-furanyl)ethenyl)-
p-7138
6-(2-(5-nitro-2-furanyl)ethenyl)-2-pyridinemethanol
2-pyridinemethanol, 6-(2-(5-nitro-2-furyl)vinyl)-
nf 323
einecs 236-503-9
p 7138
CHEBI:135000
[6-[2-(5-nitrofuran-2-yl)ethenyl]pyridin-2-yl]methanol
[6-[(e)-2-(5-nitrofuran-2-yl)ethenyl]pyridin-2-yl]methanol
NCGC00183106-01
unii-7o5a98xy8u
7o5a98xy8u ,
nifurpirinolum
CHEMBL2104627
AKOS015901192
nifurpirinol [mi]
nifurpirinol [inn]
nifurpirinol [usan]
nifurpirinol [mart.]
nifurpirinol [green book]
6-[2-(5-nitro-2-furyl)vinyl]-2-pyridinemethanol
SCHEMBL1650816
nifurpirinol, vetranal(tm), analytical standard
{6-[(e)-2-(5-nitrofuran-2-yl)ethenyl]pyridin-2-yl}methanol
DTXSID50860116
DB11436
Q10600647
MS-23481
CS-0113146
HY-135470
{6-[(1e)-2-(5-nitrofuran-2-yl)ethenyl]pyridin-2-yl}methanol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
furansCompounds containing at least one furan ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (40.00)18.7374
1990's2 (40.00)18.2507
2000's0 (0.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.74 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index66.93 (26.88)
Search Engine Supply Index4.00 (0.95)

This Compound (30.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
metronidazole
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.		7.1710C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic
9,10-dimethyl-1,2-benzanthracene
9,10-Dimethyl-1,2-benzanthracene: Polycyclic aromatic hydrocarbon found in tobacco smoke that is a potent carcinogen.. 7,12-dimethyltetraphene : A tetraphene having methyl substituents at the 7- and 12-positions. It is a potent carcinogen and is present in tobacco smoke.		1.9610ortho-fused polycyclic arene;
tetraphenes		carcinogenic agent
methylnitronitrosoguanidine
Methylnitronitrosoguanidine: A nitrosoguanidine derivative with potent mutagenic and carcinogenic properties.. N-methyl-N'-nitro-N-nitrosoguanidine : An N-nitroguanidine compound having nitroso and methyl substituents at the N'-position		1.9610nitroso compoundalkylating agent
ConditionIndicatedRelationship StrengthStudiesTrials
Fish Diseases
Diseases of freshwater, marine, hatchery or aquarium fish. This term includes diseases of both teleosts (true fish) and elasmobranchs (sharks, rays and skates).		01.9610
Malignant Melanoma
[description not available]		01.9610
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		01.9610